AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

When complications of pneumonia do develop in the pregnant patient ... Aminoglycosides should only be used if there is evidence of serious gram-negative infection, because the risk of ototoxicity ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Lefamulin has shown significant activity against gram-positive bacteria ... attainment against key pathogens like Streptococcus pneumoniae and Staphylococcus aureus [4]. This suggests that ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

Mortality rates for pneumonia caused by carbapenem-resistant A. baumannii (CRAB)—a Gram-negative pathogen—are above 50%, and more than half of A. baumannii infections are resistant to ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Methicillin-resistant Staphylococcus aureus (MRSA) is becoming an increasingly common pathogen in hospital-acquired pneumonia ... in some multidrug-resistant Gram-negative bacteria (e.g ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...